Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.

Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM.

Hepatology. 2008 Dec;48(6):1769-78. doi: 10.1002/hep.22549.

2.

[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].

Tornai I.

Orv Hetil. 2015 May 24;156(21):849-54. doi: 10.1556/650.2015.30180. Review. Hungarian.

PMID:
26038992
3.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

4.

[Telaprevir resistance].

Poveda E, García F.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Review. Spanish.

PMID:
24063900
5.

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.

Wyles DL, Gutierrez JA.

J Viral Hepat. 2014 Apr;21(4):229-40. doi: 10.1111/jvh.12230. Review.

PMID:
24597691
6.

Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.

Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O.

World J Gastroenterol. 2013 Dec 21;19(47):8940-8. doi: 10.3748/wjg.v19.i47.8940. Review.

7.

Boceprevir, an NS3 protease inhibitor of HCV.

Berman K, Kwo PY.

Clin Liver Dis. 2009 Aug;13(3):429-39. doi: 10.1016/j.cld.2009.05.008. Review.

PMID:
19628159
8.

Hepatitis C virus NS5A inhibitors and drug resistance mutations.

Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O.

World J Gastroenterol. 2014 Mar 21;20(11):2902-12. doi: 10.3748/wjg.v20.i11.2902. Review.

9.

Resistance to anti-HCV protease inhibitors.

Thompson AJ, Locarnini SA, Beard MR.

Curr Opin Virol. 2011 Dec;1(6):599-606. doi: 10.1016/j.coviro.2011.10.001. Epub 2011 Oct 28. Review.

PMID:
22440917
10.

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Halfon P, Sarrazin C.

Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x. Review.

PMID:
22212577
11.

Resistance mutations against HCV protease inhibitors and antiviral drug design.

Shang L, Lin K, Yin Z.

Curr Pharm Des. 2014;20(5):694-703. Review.

PMID:
23688081
12.

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.

Welzel TM, Dultz G, Zeuzem S.

J Hepatol. 2014 Nov;61(1 Suppl):S98-S107. doi: 10.1016/j.jhep.2014.08.014. Epub 2014 Nov 3. Review.

13.

The role of resistance in HCV treatment.

Vermehren J, Sarrazin C.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011. Review.

PMID:
23199507
14.

Emerging therapeutic options for the management of hepatitis C infection.

Thompson JR.

World J Gastroenterol. 2014 Jun 21;20(23):7079-88. doi: 10.3748/wjg.v20.i23.7079. Review.

15.

Hepatitis C virus NS3 inhibitors: current and future perspectives.

Salam KA, Akimitsu N.

Biomed Res Int. 2013;2013:467869. doi: 10.1155/2013/467869. Epub 2013 Oct 27. Review.

16.

Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.

Pillaiyar T, Namasivayam V, Manickam M.

Curr Med Chem. 2016;23(29):3404-3447. Review.

PMID:
27160539
17.

Update on different aspects of HCV variability: focus on NS5B polymerase.

Marascio N, Torti C, Liberto M, Focà A.

BMC Infect Dis. 2014;14 Suppl 5:S1. doi: 10.1186/1471-2334-14-S5-S1. Epub 2014 Sep 5. Review.

18.

Specifically targeted antiviral therapy for hepatitis C virus.

Parfieniuk A, Jaroszewicz J, Flisiak R.

World J Gastroenterol. 2007 Nov 21;13(43):5673-81. Review.

20.

Hepatitis C viral kinetics: the past, present, and future.

Chatterjee A, Smith PF, Perelson AS.

Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003. Review.

Supplemental Content

Support Center